Reframing Response in Neoadjuvant Chemotherapy for Ovarian Cancer: Integrating Molecular and Functional Biomarkers.
Combining blood tumor DNA with imaging during ovarian cancer treatment reveals biology standard pathology alone misses, sharpening decisions about surgery timing and follow-up.
This Critical Reviews in Oncology/Hematology review argues that neoadjuvant chemotherapy response assessment in ovarian cancer should move beyond conventional pathologic scoring to incorporate liquid biopsy (ctDNA, peritoneal DNA) and functional imaging, which may better capture the heterogeneity of biological response. The review synthesizes evidence on how integrated molecular-functional assessment could improve patient stratification for interval debulking surgery and adjuvant therapy decisions in platinum-sensitive disease.
What the study was
- Study design
- review
- Population
- Ovarian cancer patients receiving neoadjuvant chemotherapy (NACT)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Crit Rev Oncol Hematol
Why it surfaced
Relevant to early cancer detection (liquid biopsy for treatment monitoring) and precision oncology watchlists; addresses key clinical gap in ovarian cancer NACT response prediction; published in Critical Reviews in Oncology/Hematology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.